Is Nanobiotix S.A. (NBTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.1% / 30% | 3.0% / 30% | 0.5% / 30% | N/A | ✓ HALAL |
| DJIM | 3.1% / 33% | 3.0% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| MSCI | 75.5% / 33% | 73.8% / 33% | 12.7% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.1% / 33% | 3.0% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| FTSE | 75.5% / 33% | 73.8% / 33% | 12.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | 3.1% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -41.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$20M |
| Free Cash Flow | -$20M |
| Total Debt | $51M |
| Current Ratio | 0.6 |
| Total Assets | $67M |
Price & Trading
| Last Close | $31.32 |
| 50-Day MA | $27.16 |
| 200-Day MA | $17.74 |
| Avg Volume | 40K |
| Beta | 0.6 |
|
52-Week Range
$2.99
| |
About Nanobiotix S.A. (NBTX)
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nanobiotix S.A. (NBTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nanobiotix S.A. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nanobiotix S.A.'s debt ratio?
Nanobiotix S.A.'s debt ratio is 3.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 75.5%.
What are Nanobiotix S.A.'s key financial metrics?
Nanobiotix S.A. has a market capitalization of $1.5B, and revenue of -$12M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.